Codagenix

Codagenix

A biotechnology company developing live attenuated vaccines. It was founded in 2012 and is located in New York.

Company

Codagenix is a privately held, biotechnology company based in Stony Brook, New York. The company focuses on constructing live-attenuated viral vaccines against multiple targets using the company's proprietary technology platform, SAVE. Standing for Synthetic Attenuated Virus Engineering, the platform relies on synthetic biology and the rational 're-design' of a target virus' entire genome to yield a vaccine strain. The customization process uses software-based algorithms to 're-code' the genome of a target virus.

The company's product pipeline includes vaccines for influenza, respiratory syncytial virus (RSV), dengue, foot and mouth disease virus (FMDV), pathogenic E. Coli, and other targets.

COVID-19

In February 2020, the company teamed up with the Serum Institute of India to co-develop a live-attenuated vaccine for COVID-19. The company uses viral deoptimization technology in order to create multiple vaccine candidates for a virus.

Timeline

People

Name
Role
LinkedIn

Eckard Wimmer

Co-Founder, Senior Scientific Officer

J. Robert Coleman

Co-Founder & COO

Rishab Kaul

Employee

Steffen Mueller

Co-Founder, President, and Chief Scientific Officer

Further reading

Title
Author
Link
Type
Date

Codagenix and Serum Institute of India Initiate Co-Development of a Scalable, Live-Attenuated Vaccine Against the 2019 Novel Coronavirus, COVID-19

Web

February 13, 2020

Xconomy: With $2M, Codagenix Becomes Accelerate LI's First VC-Backed Grad

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.